Voyager Therapeutics Announces Positive Longer-Term Data for VY-AADC for Parkinson’s Disease
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/6/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Voyager Therapeutics (VYGR) PT Lowered to $27 at Baird
November 8, 2018 8:44 AM ESTBaird analyst Brian Skorney lowered the price target on Voyager Therapeutics (NASDAQ: VYGR) to $27.00 (from $31.00) while maintaining a Outperform rating.
The analyst commented, "After initially indicating that the Phase 2 study Voyager is about to start could be fileable, the FDA recently notified Voyager... More
